AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CollPlant Biotechnologies Ltd.
Video analysis: CLGN
All videosNo video analysis for this stock yet. Request one from our team.
News: CLGN
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology REHOVOT, Israel, Sept. 4, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand engagements with strategic partners. REHOVOT, Israel, Sept.
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing LightSolver has developed the world's first Laser Processing Unit™ (LPU™), combining the advantages of classical and quantum computing in a compact platform that operates without cryogenic or other extreme conditions and is designed for commercial deployment. Commercial validation is underway with global leaders across mission-critical industries, including Boeing, a top-tier global financial institution, leading defense companies, oil and gas and energy companies, and leading engineering software organizations.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined purchase price of $0.34 per ordinary share and accompanying warrants (or $0.3399 per ordinary share equivalent and accompanying warrants). The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants.
